LDS/Medical Tests/Fabry Disease (GLA) Gene Mutation Analysis

Fabry Disease (GLA) Gene Mutation Analysis

Fabry disease, also known as Anderson–Fabry disease is an X-linked, lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A, encoded by the GLA gene. Over 800 mutations in this gene have been identified that alter the structure and function of the enzyme, preventing it from breaking down globotriaosylceramide (GL-3) which then accumulates in the lysosomes of cells throughout the body. Clinically Fabry disease is characterized by skin angiokeratomas, sweating abnormalities (anhidrosis, hypohidrosis or rarely hyperhidrosis), corneal and lenticular opacities, stroke, neuropathic pain in the extremities (acroparesthesia), cardiac disease (including left ventricular hypertrophy), and renal disease (proteinuria progressing to end stage renal disease). Affected males with frameshift or nonsense mutations typically have < 1% of normal alpha-galactosidase A activity and present with classic Fabry features in childhood or adolescence. Those men with missense mutations may present with classic Fabry, or with atypical phenotypes characterized by higher enzyme levels and late onset cardiac and/or renal disease. Heterozygous female carriers may be clinically normal or present with classic Fabry features due to random X-chromosome inactivation. The disease affects 1:50,000 to 1:117,000 males.
  • Diagnostic confirmation of classic or variant Fabry disease in affected males and females with reduced alpha-Gal A enzyme activity
  • Carrier screening in family members of the affected patient
  • Prenatal diagnosis in at-risk pregnancies
Mutation or pathogenic variant in GLA gene is consistent with a diagnosis of Fabry disease. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No mutation or pathogenic variant detected)

Next-Generation (NGS)/Massively parallel sequencing (MPS), Conventional sequencing.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
α-Gal A enzyme analysis, Lyso Gb3 biomarker analysis, GLA deletion/duplication analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login